1 day ago · Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray …

1 day ago · The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment …

There’s good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy that can provide relief from major depression within hours.

2 days ago · The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least …

Jan 22, 2025 · In a significant step forward for mental health care, the U.S. Food and Drug Administration (FDA) has expanded its approval of Spravato (esketamine) nasal spray. Initially …

Jan 21, 2025 · The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat …

Esketamine nasal spray is recommended for adults diagnosed with major depressive disorder (MDD) who did not respond to at least two antidepressants, and who currently have a major …

Oct 4, 2023 · In this trial involving patients with treatment-resistant depression, esketamine nasal spray was superior to the comparator, extended-release quetiapine, a commonly used …

Jul 12, 2019 · Esketamine helps create more of those connections between the brain cells. That may ease symptoms of depression. Esketamine also has been shown to decrease suicidal …

Intranasal esketamine has shown efficacy in reducing depressive symptoms in clinical trials, but the clinical meaningfulness of the treatment effect in the real-world population still needs to be …